Offene Studien fortgeschritten
| Name | Titel |
|---|---|
| BO41843 | A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| Detect V | A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Pertuzumab in patients with HER2 positive and hormone-receptor positive metastatic breast cancer. |
| Destiny Breast 12 | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12) |
| EPIK B3 | A phase III, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation |
| INAVO (WO41554) | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC‑0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PIK3CA-MUTANT HORMONE RECEPTORPOSITIVE, HER2‑NEGATIVE BREAST CANCER |
| KeyNote-587 | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. |
Nutrition | Prospektive, randomisierte, monozentrische Studie zum Einfluss einer intensiven Ernährungsberatung auf die Lebensqualität bei Patienten mit metastasiertem Brustkrebs unter CDK4/6- oder mTOR-Inhibition |
Palmira | International, multicenter, randomized, open-label, phase II clinical trial to evaluate the efficacy and safety of continuation of palbociclib in combination with second-line endocrine therapy in Hormone Receptor-positive/HER2-negative advanced breast cancer patients who have achieved clinical benefit during first-line palbociclib-based treatment. |
PRAEGNANT | Prospektives akademisches translationales Forschungsnetzwerk zur Optimierung der onkologischen Versorgungsqualität in der adjuvanten und fortgeschrittenen/ metastasierten Situation (Registerstudie) |